Seattle-based Omeros Corporation, a clinical-stage biopharmaceutical firm, is making strides in the discovery, development, and commercialization of small-molecule and protein therapeutics, targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. Boasting a diverse range of clinical programs, the company's Narsoplimab (OMS721/MASP-2) has completed pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is now in Phase III clinical trials for immunoglobulin A nephropathy (IgAN), with a Phase II clinical trial underway to treat COVID-19. Additionally, Omeros is actively developing OMS1029 for long-acting second-generation antibody targeting lectin pathway disorders and OMS906 for clinical trials to treat conditions such as Paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Omeros also has OMS527, which is in a Phase I trial for addictive and compulsive disorders as well as movement disorders, and OMS405 in Phase II clinical trials for opioid and nicotine addiction. The company is investigating MASP-2-small-molecule inhibitors for the treatment of atypical hemolytic uremic syndrome, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors; chimeric antigen receptor T-Cell therapies for cancer; and G protein-coupled receptors for treating a range of disorders. Omeros Corporation was founded in 1994 and continues to advance its mission to bring novel treatments and therapies to patients in need.
Omeros Corp's ticker is OMER
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 51-200 employees working at Omeros Corp
It is omeros.com
Omeros Corp is in the Healthcare sector
Omeros Corp is in the Biotechnology industry
The following five companies are Omeros Corp's industry peers: